Mesquite Allergy Shots: The Desert's Olive-Linked Aeroallergen
Mesquite (Prosopis juliflora, P. velutina, P. glandulosa) is the dominant spring aeroallergen across the Sonoran, Chihuahuan, and Mojave Deserts — unique among Fabaceae trees in being substantially wind-pollinated. Its major allergen Pro j 1 is an Ole e 1-like protein that cross-reacts with olive, ash, and privet, creating an unexpected Southwest-to-California connection.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Mesquiteis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Mesquite Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to mesquite — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of mesquite allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of mesquite immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of mesquite extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for mesquite allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing mesquite extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription mesquite immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat mesquite allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Mesquite?
The biology, taxonomy, and clinical fingerprint of Mesquite — the foundation of how SCIT targets it.
Mesquite (Prosopis) pollen grains at 30–36 μm are far smaller than pine pollen and well within the respirable range — explaining why mesquite is the legitimate Southwest aeroallergen despite its legume family origin.
- Scientific name
- Prosopis juliflora, P. velutina, P. glandulosa
- Family
- Fabaceae (subfamily Mimosoideae)Legume family
- Type
- Wind-pollinated legume tree pollen — unusual within Fabaceae
- Native to
- Sonoran, Chihuahuan, and Mojave Deserts; Texas, New Mexico, Arizona, southern California, Oklahoma, Louisiana
- Allergen proteins
- Pro j 1 (major) — Ole e 1-like protein, 16.5 kDaPro j 2 — Profilin, 14 kDa
- Particle size
- 30–36 μm (3-colporate, triangular amb) — well within respirable range
- Avoidance difficulty
- Nearly impossible
How Mesquite Allergy Presents
Symptoms by body system — useful for distinguishing Mesquite sensitivity from overlapping allergies and infections.
Respiratory
- Seasonal allergic rhinitis with onset April through July in the Southwest desert
- Nasal congestion and sneezing coinciding with 200–600 grains/m³ mesquite counts at Phoenix and Tucson NAB stations
- Asthma exacerbation — Novey 1977 JACI documented positive bronchial challenges in sensitized patients
- Extended late-summer symptom burden in irrigated areas where mesquite pollination continues past July
Ocular
- Itchy, watery eyes during peak April–July desert pollen events
- Allergic conjunctivitis — a common comorbidity in Southwest mesquite-allergic patients
- Periorbital swelling in more sensitized individuals during peak exposure
Dermal
- Contact urticaria from mesquite wood, bark, or seed pods (distinct from pollen IgE)
- Oral allergy syndrome (tingling, throat tightening) with melon, banana, and watermelon via Pro j 2 profilin
- Skin reactivity to mesquite bean flour in occupational exposure settings (rare)
Systemic
- Fatigue from chronic spring and summer nasal inflammation in the Southwest desert
- Reduced outdoor work capacity for the extended April–July mesquite season
- Food-pollen syndrome — mouth tingling and throat symptoms with profilin-containing foods (melon, banana, watermelon, tomato, citrus) via Pro j 2
What surprises patients about mesquite is the olive link. A patient who tests positive to mesquite in Phoenix and then moves to California where olive trees are everywhere — the same Pro j 1 protein cross-reacts with olive Ole e 1, and suddenly their allergy follows them. We counsel on both before they relocate.
When & Where Mesquite Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through June; extended into late summer in irrigated Sonoran Desert communities· 4–6 months of significant airborne mesquite pollen in irrigated desert regions — unusually long for a tree allergen
US Exposure Map
3 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Moderate
- NV:
- Moderate
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- High
- NM:
- High
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- Moderate
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- High
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Mesquite Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Mesquite's two named allergens create two distinct cross-reactivity pathways: Pro j 1 (Ole e 1-like) connects mesquite to the entire Oleaceae family — olive, ash, privet, Russian olive — while Pro j 2 profilin connects it to dozens of unrelated pollens and foods.
Pro j 1 is an Ole e 1-like protein — strong structural homology documented by RAST inhibition
Southwest-co-occurring ash species with Ole e 1-like cross-reactivity via Pro j 1
Fabaceae family cross-reactivity; acacia sensitization often driven by primary mesquite IgE
Pro j 2 profilin cross-reacts with profilin-containing foods including melon, banana, watermelon
Profilin cross-reactivity via Pro j 2 — mouth tingling common in confirmed mesquite-allergic patients
Mesquite Profilin-Food Syndrome
Pro j 2 profilin drives oral allergy syndrome with profilin-rich plant foods. Symptoms are typically mild (mouth and throat tingling) and cooked food is usually tolerated — cooking denatures profilins. Consult your allergist if reactions are more than mild.
Is SCIT Right for Your Mesquite Allergy?
Answer five questions to assess whether mesquite allergy shots are the right immunotherapy option for your Southwest spring symptoms.
How severe are your spring symptoms during April–July in the Southwest desert?
The Mesquite SCIT Protocol
Mesquite SCIT follows the standard inhalant build-up schedule using a non-standardized extract; many Southwest allergists include mesquite in a regional mix alongside olive and ash to cover Pro j 1 cross-reactive allergens in a single vial set.
Weekly injections escalate the mesquite extract from a dilute starting concentration over 16–24 weeks. With Curex, eligible patients run this conservative once-weekly build-up at home — Curex does not offer rush or cluster schedules. The first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a 30-minute observation follows each injection. Pro j 2 profilin sensitization does not increase injection-site reactions but should prompt profilin-food syndrome counseling.
Maintenance injections at the target maintenance dose on a schedule individualized by your allergist, each followed by a 30-minute observation. With Curex, you self-inject the maintenance dose at home, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room. Because mesquite season extends into late summer in irrigated areas, maintenance timing may be adjusted to avoid dosing on high-pollen days. Your allergist may also include concurrent olive and/or ash extract in the maintenance vial set given Pro j 1 cross-reactivity.
After completing the standard course, clinical response — not published RCT endpoints — guides discontinuation. Many Southwest allergists assess at 3 years and continue if significant symptoms remain during the extended desert season.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Mesquite SCIT
Mesquite has the strongest biological case of any Fabaceae tree allergen — named IUIS allergens and bronchial-challenge evidence (Novey 1977) — but no placebo-controlled SCIT trial has been published. Clinical experience in the Southwest suggests benefit in confirmed-sensitized patients.
- Positive bronchial challenge responses in mesquite-sensitized patients80%Novey HS et al., J Allergy Clin Immunol, 1977 — bronchial provocation series
- Unique IgE-binding proteins identified in velvet mesquite proteomics24%Huerta-Ocampo JA et al., Life, 2022;12(9):1421 — proteomics analysis of P. velutina
- Inhalant SCIT symptom reduction (class-level extrapolation)60%Cox L et al., JACI, 2011 — AAAAI Practice Parameter meta-summary
Mesquite is the most clinically legitimate Fabaceae aeroallergen in the US — two IUIS-named allergens, bronchial-challenge evidence, and high regional sensitization rates in the Southwest. However, no SCIT RCT has been published, which remains a significant evidence gap given the scale of mesquite's Southwest impact. Clinical benefit in confirmed patients is extrapolated from the inhalant SCIT class.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Mesquite SCIT Side Effects
Mesquite SCIT carries the standard inhalant SCIT side-effect profile. Pro j 2 profilin sensitization does not increase systemic reaction risk from injections, though patients should be counseled about profilin-food reactions separately.
Local reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Most common; resolves within hours | Rate 30–50% | Mild |
Injection-site redness and itching More frequent at concentration step-ups during build-up | Rate 20–40% | Mild |
Large local reaction (>5 cm) Prompts dose reduction; not predictive of systemic reaction | Rate 5–15% | Moderate |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria Requires epinephrine — a prescribed auto-injector is confirmed on hand — and extended observation during your supervised 30-minute window | Rate <1% | Moderate |
Rhinitis or conjunctivitis flare Temporary post-injection exacerbation of nasal or eye symptoms | Rate 1–3% | Mild |
Anaphylaxis A 30-minute observation follows every injection; with Curex this is self-observation at home with dosing supervised live in the Virtual Shot Room | Rate <0.01% per injection | Severe |
A 30-minute post-injection observation is a non-negotiable AAAAI safety standard for all SCIT. With Curex, eligible patients self-administer at home — the serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on hand, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room. Southwest patients should also be counseled separately about profilin-food reactions, which are independent of injection risk.
SCIT vs Alternatives for Mesquite
Mesquite-allergic Southwest patients have four main management approaches: SCIT (the most immune-modifying option), sublingual drops, avoidance (limited given urban desert ecology), and daily symptom-control medications.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate-high (bronchial challenge evidence; no RCT) | Emerging; no mesquite-specific RCT | Limited — dominant desert landscape | Symptomatic relief only |
| 5-yr cost | $3,500–$15,000 | Varies by provider; not Curex's product | Low | $500–$2,000/year |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | At-home weekly self-injection during build-up | Daily drops at home | HEPA filters, windows closed April–July | Daily pills/sprays |
| Safety | USP <797> serum; Virtual Shot Room–supervised dosing; 30-min self-observation | Lower systemic reaction risk vs SCIT | Safe | Safe; antihistamine sedation risk |
| Lasting effect | Possible lasting tolerance | Possible lasting benefit | No immune modification | No lasting effect |
SCITBest
SLIT
Avoidance
Medications
For the many Southwest patients without easy access to allergists offering non-standardized mesquite SCIT, Curex now delivers disease-modifying SCIT at home with pricing confirmed in a current program quote — covering mesquite and its cross-reactive Oleaceae allergens. The serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector is confirmed on hand under board-certified allergist oversight.
What Mesquite SCIT Actually Costs
Most major Southwest insurers cover mesquite SCIT under standard allergy benefits when ordered by a board-certified allergist with documented sensitization. Non-standardized extract may require prior authorization in some plans. Because mesquite is often prescribed alongside olive and ash in a Southwest regional mix, verify that the full vial set is covered before starting. Curex at-home IgE testing identifies specific mesquite sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your mesquite allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Mesquite SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Mesquite's major allergen Pro j 1 is an Ole e 1-like protein — the same structural family as olive's major allergen Ole e 1 and ash's Fra e 1. This molecular homology, demonstrated by RAST inhibition studies, means IgE antibodies raised against mesquite's Pro j 1 can bind olive and ash allergens and trigger symptoms. The practical consequence is significant: a patient sensitized to mesquite in Phoenix who moves to the California coast — where olive trees are common — may find their allergy 'follows them.' A board-certified allergist should screen for concurrent olive and ash sensitization in all mesquite-positive Southwest patients.
Most Fabaceae trees are bee-pollinated, with sticky pollen that does not become airborne. Mesquite is unusual within the legume family in being substantially wind-pollinated — its flowers produce small (30–36 μm), dry, 3-colporate pollen that is efficiently launched into the desert air. Novey et al. (J Allergy Clin Immunol, 1977) confirmed this by demonstrating positive bronchial provocation challenges in mesquite-sensitized patients — the gold standard for establishing aeroallergen status. Palo verde and acacia, by contrast, are bee-pollinated and do not achieve meaningful airborne concentrations.
Mesquite SCIT targeting Pro j 2 profilin may reduce pollen-food syndrome symptoms over time, but profilin-food reactions are typically mild (mouth and throat tingling) and self-limiting — they do not usually require immunotherapy on their own. Cooking the foods in question denatures profilins and usually eliminates the reaction. If profilin-food reactions are more severe (throat tightening, systemic symptoms), a board-certified allergist should evaluate whether the reaction is profilin-mediated or involves a more stable allergen protein. Discuss the expected impact of mesquite SCIT on your specific food reactions with your allergist.
No randomized placebo-controlled trial has been published specifically for mesquite SCIT, which is a significant gap given mesquite's major regional impact in the Southwest. The clinical evidence base includes Novey et al. 1977 JACI bronchial-challenge data establishing mesquite as a true aeroallergen, two WHO/IUIS-named allergens (Pro j 1, Pro j 2), and Huerta-Ocampo et al. 2022 Life documenting 24 unique IgE-binding proteins in P. velutina. Southwest allergy practices report clinical benefit in confirmed-sensitized patients, but this extrapolates from inhalant SCIT class evidence rather than a mesquite-specific trial. Your allergist should present this evidence gap as part of informed consent.
The key clinical distinction is pollination biology. Mesquite (Prosopis) is substantially wind-pollinated and achieves counts of 200–600 grains/m³ at Phoenix and Tucson NAB stations — establishing it as a legitimate aeroallergen. Acacia is predominantly bee-pollinated with showy yellow flower clusters; its polyad pollen morphology limits airborne transport. Mesquite has two IUIS-named allergens (Pro j 1, Pro j 2); acacia has none. In the Southwest, most acacia sensitization likely reflects mesquite primary sensitization with Fabaceae cross-reactivity. A board-certified allergist distinguishes these with separate skin tests or ImmunoCAP results.
Most major US health insurers in Texas and Arizona cover inhalant SCIT under standard allergy benefits when ordered by a board-certified allergist with documented sensitization. Mesquite extract is non-standardized — some plans require prior authorization citing clinical necessity. Southwest regional allergy practices frequently prescribe mesquite in a multi-allergen vial alongside olive, ash, and mulberry; verify that the full Southwest mix is covered under your plan. CPT codes 95115, 95117, and 95165 are standard. Confirm in-network allergist status before starting, as Southwest specialty allergy access varies significantly outside major cities.
Climate models suggest that desert Southwest warming and expanded CO2 will likely increase mesquite pollen season duration and production. Irrigated urban expansion in Phoenix and Tucson has already extended the mesquite flowering season beyond its natural calendar. Published climate-pollen analyses (Rogers et al., multiple journals) project longer allergy seasons for dominant Southwest aeroallergens including mesquite. If your symptoms have worsened over the past decade, this is consistent with the regional trend. A board-certified allergist can help assess whether SCIT is warranted given the likely multi-decade burden.
Children can receive inhalant SCIT for mesquite provided they meet standard candidacy criteria: confirmed mesquite-specific IgE sensitization, inadequate symptom control with medications, and appropriate age (most allergists begin no earlier than age 5–6). For Southwest children, a full panel including mesquite, olive, mulberry, and Bermuda grass should precede any SCIT prescription — overlapping Southwest allergens are common in pediatric patients. If the child also has asthma, a pediatric pulmonologist should assess SCIT candidacy alongside the allergist, given mesquite's documented bronchial provocation activity. Note: Curex's at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection. On safety, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.